RainSure Scientific Completes Tens of Millions of RMB Series B1 Financing Led by Qingke Asset Management

Recently, RainSure SCIENTIFIC (hereinafter referred to as “RainSure”) announced in Suzhou Industrial Park that it had completed a B1 round of financing amounting to tens of millions of yuan. This round was led by Zero2ipo Asset Management, with participation from Kaitai Capital, while existing shareholders Mingshi Capital and Volcanics Venture continued to increase their investment. Benchu Capital served as the exclusive financial advisor.

According to reports, this round of financing will be used for the research and development and registration of digital PCR-based in vitro diagnostic kits, the construction of GMP-compliant manufacturing facilities, the strengthening of the domestic sales team and distributor network, and the consolidation of overseas sales channels established during the COVID-19 pandemic. Previously, RainSure Scientific secured over RMB 100 million in investment across three rounds from ZhenFund, Volcanics Venture, Mingshi Capital, and YSVC.

RainSure SCIENTIFIC was established in October 2017. With the mission of “Innovation, Intelligent Manufacturing, and Serving Health,” the company is dedicated to driving innovative applications of leading technologies, including digital PCR, in fields such as scientific research, in vitro diagnostics, and inspection and quarantine.

Its founding members all hold Ph.D. degrees from top-tier universities such as the U.S. Ivy League institutions and have long served at prestigious biotechnology companies in the industry. They have repeatedly participated in and led the development of multiple well-known industry products, possessing a solid academic background and extensive industrial experience.

The RainSure DropX-2000 system requires operators to perform only manual sample loading and chip transfer, making it one of the most highly automated digital PCR products currently on the market. It is also the only digital PCR product officially available with a “grand slam” of three major regulatory approvals: NMPA, FDA-EUA, and CE-IVD. Closely aligning with customer needs, RainSure Scientific is accelerating the development of a fully automated, highly integrated digital PCR system designed to address critical clinical pain points and enable a transformative upgrade in the clinical application of molecular diagnostics. During the pandemic, RainSure’s digital PCR systems served multiple anti-epidemic institutions, including Huoshenshan Hospital, Nantong Third People’s Hospital, the National Institute of Metrology of China, and the Jiangsu Provincial Center for Disease Control and Prevention.

RainSure Microfluidics currently serves numerous clients in China, Europe, and the United States. It has become one of the top three suppliers of microfluidic research equipment in Europe and the United States. Its representative clients include prestigious domestic and international universities such as Harvard University, Princeton University, MD Anderson Cancer Center, Georgia Institute of Technology, Virginia Tech, University of California, Irvine, University of Ottawa, ShanghaiTech University, Shanghai Jiao Tong University, and The University of Hong Kong, as well as renowned enterprises including Pfizer, Merck, Complete Genomics, and Eurofins.

During the COVID-19 pandemic, RainSure Scientific launched a series of diagnostic products based on quantitative fluorescent PCR technology, including one-step detection kits without nucleic acid extraction, rapid detection kits, digital PCR COVID-19 detection kits, and multiplex PCR detection kits targeting SARS-CoV-2 variants. Leveraging superior product quality and responsive customer service, RainSure’s COVID-19 solutions have served the Ministry of Health of Burkina Faso, Germany’s SYNLAB Group, as well as numerous renowned laboratories and third-party testing laboratory groups in Europe. Meanwhile, RainSure Scientific has established an overseas sales team of five members based in Germany, currently serving users in Germany, the Czech Republic, the United Kingdom, Austria, and Luxembourg. The company has also built distributor networks in Germany and the Czech Republic. In 2020, overseas sales accounted for 70% of RainSure Scientific’s total revenue.

Following this round of financing, RainSure SCIENTIFIC will continue to advance the implementation of digital PCR applications in clinical diagnostics within China, strengthen its teams for clinical product R&D and registration as well as marketing and sales, and deliver innovative solutions to clinical customers.

RainSure Scientific revealed, “In the future, we will develop an all-in-one digital PCR system that is more integrated, compact, and portable. We will also continue to research and develop new equipment products in the field of molecular diagnostics. In terms of test kits, we will actively expand our presence in areas such as tumor liquid biopsy, infectious diseases, and companion diagnostics, developing application-oriented products that meet market demands.”

In terms of its marketing team, RainSure SCIENTIFIC has recruited several seasoned industry veterans from both China and abroad, who possess extensive experience in the operation and management of large-scale international diagnostic instrumentation. Meanwhile, the company is actively building a “direct sales + distributor” network, aiming to collaborate with industry peers to rapidly increase its market share in both domestic and international markets.

RainSure SCIENTIFIC stated, “In the future, we aspire to become a globally leading life sciences company headquartered in China. Our short-term goal is to establish a significant voice in our specialized niche markets by leveraging the performance and quality advantages of our products, as well as our superior service capabilities.”

The RainSure team stated: “RainSure SCIENTIFIC will continue to deepen its commitment to the digital PCR sector and actively expand its presence in the field of molecular diagnostics. Leveraging strong R&D capabilities, the company has adhered to independent innovation since its inception, maintaining a pragmatic and low-profile approach while rapidly launching multiple products that have consistently received positive feedback from customers for their quality. The company has achieved revenue growth exceeding 500% for three consecutive years and has garnered numerous industry accolades. RainSure SCIENTIFIC remains dedicated to developing valuable molecular diagnostic products and delivering high-quality user value. With a focus on strengthening its position in China and establishing a global footprint, the company aims to become a world-class, enduring enterprise through superior product quality.”

“Zero2ipo Asset Management, the lead investor in this round, is one of China’s earliest established investment firms and a leading integrated platform for entrepreneurship and investment services as well as a renowned investment institution. Upon completion of this strategic investment, we are confident that, together with Zero2ipo Asset Management, we will accelerate the development of the digital PCR ecosystem and drive the company’s rapid growth.”

Ms. Yang Min, Managing Partner of Zero2ipo Asset Management, as the lead investor in this roundindicates: Digital PCR (dPCR) belongs to the third generation of PCR technology and is a platform-based technology characterized by absolute quantification, high sensitivity, and high specificity. It has a wide range of applications, including liquid biopsy for cancer, microbiology, infectious diseases, genetic disease diagnosis, and companion diagnostics. As usage costs continue to decrease and operational convenience improves, dPCR is expected to replace second-generation PCR in certain fields.

RainSure Scientific is a leading enterprise in the field of digital PCR. Its team members hold doctoral degrees from top U.S. universities and have long served at globally renowned biotechnology companies. Since its establishment, RainSure has achieved rapid growth and demonstrated strong execution capabilities. Its digital PCR instruments feature a high degree of automation, and they are currently the only digital PCR products on the market that have officially secured the “grand slam” of three major certifications: NMPA approval, FDA Emergency Use Authorization (EUA), and CE-IVD marking. Furthermore, in 2020, RainSure Scientific further expanded into overseas markets and accelerated its internationalization strategy.

We firmly support the company’s development and believe that, under the leadership of RainSure SCIENTIFIC’s core team, the company will develop more outstanding products to benefit society.

Mr. Zhang Taihao, Vice President of Kaitai Capital, participated in this round of follow-on investmentIndicates: Kaitai Capital has always adhered to value discovery. The underlying technology of digital PCR, centered on microfluidic droplet generation, represents the future trend of single-molecule detection. Data from NCBI shows a rapid increase in research adopting digital PCR, with explorations in the scientific research field providing forward-looking insights for new clinical applications and standards. Kaitai Capital believes that in the future of commercial globalization, the team at RainSure SCIENTIFIC possesses the technical expertise and connectivity capabilities to participate in global competition, with potential for expansion beyond digital PCR.

RainSure Scientific was established in 2017. Since its inception, RainSure Scientific has adhered to the philosophy of “global R&D, intelligent manufacturing in China,” taking innovation, smart manufacturing, and health advancement as its core mission, with a focus on frontier technological innovation and product development in the broader healthcare sector. Currently, RainSure Scientific’s product portfolio encompasses three major segments: digital PCR systems, microfluidic solutions, and in vitro diagnostic reagents. The company has established a research, development, and production base in Suzhou Industrial Park and has obtained ISO 13485 quality management system certification from SGS (Société Générale de Surveillance).

RainSure SCIENTIFIC has received widespread international acclaim, having been awarded the Championship in the Western US Division of the China Association for Science and Technology’s inaugural Overseas Entrepreneurship Competition, recognized as a Leading Entrepreneurial Enterprise in Suzhou Industrial Park (2018), named a Gusu Angel Investment Enterprise (2018), selected as a Project Implementation Unit for Jiangsu Province’s Innovation and Entrepreneurship Program for Returned Overseas Scholars (2018), and certified as a High-Tech Enterprise (2019).

In 2019, RainSure SCIENTIFIC’s digital PCR system, DropX-2000, won the “Annual Outstanding New Scientific Instrument Award” in China’s scientific instrument industry, selected from over 9,000 new models released by nearly 1,500 companies. In 2020, RainSure SCIENTIFIC was recognized as one of the Top 20 companies in molecular diagnostics on the Future Healthcare 100 list and ranked among the Top 20 innovative medical device enterprises in China’s healthcare sector, and wasGlobal Market Research FirmNamed by CB Insights as one of the 41 most promising molecular diagnostics companies in China, and awarded the Bronze Prize in the “COVID-19 Pandemic Response” category of the inaugural Medical Science and Technology Innovation Competition organized by the National Health Commission.

Zero2ipo Asset Management, established in 2012 as a subsidiary of the Zero2ipo Group, specializes in providing strategic industrial layout and mid-to-long-term asset management and investment services to listed companies and family enterprises.

Leveraging Zero2ipo Group’s in-depth understanding of China’s private equity industry and its comprehensive suite of services—including research, conferences, consulting, and investment—Zero2ipo Asset Management actively uncovers enterprise and market value to realize the philosophy of value investing.

Zero2ipo Asset Management has established strategic industrial funds in collaboration with multiple listed companies, such as Longfor Properties, Pien Tze Huang, Lingnan Landscape, Lanxum, Urovo, and Yaoji Playing Cards. It also manages dozens of family funds. Currently, Zero2ipo Asset Management oversees assets under management exceeding RMB 20 billion. More than just a financial investor, Zero2ipo Asset Management leverages its industrial resources to assist enterprises in strategic planning and resource integration, accelerating corporate growth and driving local industrial development, thereby creating a win-win scenario for listed companies, portfolio companies, funds, and local governments.

Kaitai Capital, established in 2009, is a professional venture capital management firm primarily engaged in innovation investment, industrial investment, and wealth management. Currently, Kaitai Capital manages over RMB 50 billion in assets, with four core investment sectors: medicine and biotechnology, digital health and digital healthcare, artificial intelligence and the digital industry, and community innovation and consumption upgrading.

Benchu Capital, established in 2016, is a boutique investment bank headquartered in Shanghai. Guided by an industry-driven approach, it has successively entered the education, artificial intelligence, enterprise services, and healthcare sectors, providing financing and financial advisory services to high-growth companies. Meanwhile, Benchu Capital has built an investment banking cooperation network across multiple countries worldwide, enabling it to deliver cross-border M&A investment banking services to clients both domestically and internationally.